- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05882942
Matcha Green Tea Effects at Rest and During Moderate-intensity Exercise in Females
May 26, 2023 updated by: Mark Eilisabeth Willems, University of Chichester
Effects of Matcha Green Tea on Heart Rate Variability, Substrate Oxidation and Cardiovascular Response at Rest and During Moderate-intensity Exercise in Females
Intake of the green tea catechin epigallocatechin (EGCG) increased fat oxidation during walking.
It is also known to reduce blood pressure and improve body composition.
This research will expand the insight on the effects by Matcha green tea supplementation and address the effects on heart rate variability, substrate oxidation at rest, and cardiovascular responses at rest in addition to metabolic and physiologic responses for a 1-hr walk in healthy females.
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Detailed Description
Intake of the catechin epigallocatechin (EGCG) increased fat oxidation during walking.
It is also known to reduce blood pressure and improve body composition.
EGCG is the most abundant and potent bioactive compound (50-80% of the total catechin content) found in Matcha green tea (MGT) and is usually consumed as a drink or in a capsulated from unfermented tea leaves.
MGT polyphenols have antioxidant and anti-inflammatory properties, providing numerous health benefits, such as the reduced risk of type 2 diabetes and obesity.
MGT supplementation (3g over a 24hr period) has been shown to enhance fat oxidation during 30-min brisk walking as well as lower respiratory exchange ratio in females.
Understanding the effectiveness of the bioactive compounds found in natural food sources in improving human health is key to informing the general population and the public health policies preceding them; the daily consumption of drinks and food naturally high in EGCG content could be recommended as an essential part of a healthy lifestyle.
This research will expand the insight on Matcha green tea supplementation address the effect on heart rate variability, substrate oxidation at rest, and cardiovascular responses at rest in addition to metabolic and physiologic responses for a 1-hr walk in healthy females.
Study Type
Interventional
Enrollment (Estimated)
14
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Mark E Willems, PhD
- Phone Number: +4401243816468
- Email: m.willems@chi.ac.uk
Study Contact Backup
- Name: Charles Green, PhD
- Email: c.green@chi.ac.uk
Study Locations
-
-
-
Chichester, United Kingdom
- Recruiting
- University of Chichester
-
Contact:
- Mark Willems
-
-
West Sussex
-
Chichester, West Sussex, United Kingdom, PO19 6PE
- Recruiting
- Mark Willems
-
Contact:
- Charles Green, PhD
- Email: c.green@chi.ac.uk
-
Contact:
- Mark E Willems, PhD
- Phone Number: 07807604749
- Email: m.willems@chi.ac.uk
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Adult
Accepts Healthy Volunteers
Yes
Description
Inclusion Criteria:
- healthy
- non-smokers
- not taking any supplements
- no known allergy to green tea
Exclusion Criteria:
- smokers
- known high blood pressure
- on medication
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Placebo
Participants will be supplemented with a placebo.
|
This is the condition with the placebo
|
Experimental: Matcha green tea
Participants will be supplemented with Matcha green tea.
|
This is the condition with the Matcha green tea
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Heart rate variability
Time Frame: Three weeks
|
Measurement of root mean square of standard deviation of RR intervals
|
Three weeks
|
Carbohydrate oxidation
Time Frame: Three weeks
|
Measurement of carbohydrate oxidation in grams/minute
|
Three weeks
|
Fat oxidation
Time Frame: Three weeks
|
Measurement of fat oxidation in grams/minute
|
Three weeks
|
Cardiac output
Time Frame: Three weeks
|
Measurement of cardiac output in liters per minute
|
Three weeks
|
Stroke volume
Time Frame: Three weeks
|
Measurement of stroke volume in milliliters
|
Three weeks
|
Total peripheral resistance
Time Frame: Three weeks
|
Measurement of total peripheral resistance in (mmHg x min) / mL
|
Three weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Mark E Willems, University of Chichester
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
March 3, 2023
Primary Completion (Estimated)
July 26, 2023
Study Completion (Estimated)
August 15, 2023
Study Registration Dates
First Submitted
May 17, 2023
First Submitted That Met QC Criteria
May 26, 2023
First Posted (Actual)
May 31, 2023
Study Record Updates
Last Update Posted (Actual)
May 31, 2023
Last Update Submitted That Met QC Criteria
May 26, 2023
Last Verified
May 1, 2023
More Information
Terms related to this study
Other Study ID Numbers
- 22231905455
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on No Condition
-
Dompé Farmaceutici S.p.ACompleted
-
Dompé Farmaceutici S.p.ACompleted
-
Dompé Farmaceutici S.p.ACompleted
-
Zambon SpACompleted
-
Virginia Polytechnic Institute and State UniversityUniversity of Maryland, Baltimore; Family Services, Inc.; Skillsource Group,... and other collaboratorsTerminatedNo ConditionUnited States
-
Federico II UniversityCompleted
-
Herlev and Gentofte HospitalCompleted
-
NYU Langone HealthNew York City Health and Hospitals CorporationCompleted
Clinical Trials on Placebo
-
SamA Pharmaceutical Co., LtdUnknownAcute Bronchitis | Acute Upper Respiratory Tract InfectionKorea, Republic of
-
National Institute on Drug Abuse (NIDA)CompletedCannabis UseUnited States
-
AstraZenecaParexel; Spandauer Damm 130; 14050; Berlin, GermanyCompletedMale Subjects With Type II Diabetes (T2DM)Germany
-
Heptares Therapeutics LimitedCompletedPharmacokinetics | Safety IssuesUnited Kingdom
-
GlaxoSmithKlineCompletedPulmonary Disease, Chronic ObstructiveUnited Kingdom, Netherlands
-
ItalfarmacoCompletedBecker Muscular DystrophyNetherlands, Italy
-
Shijiazhuang Yiling Pharmaceutical Co. LtdXuanwu Hospital, BeijingCompleted
-
GlaxoSmithKlineCompletedInfections, BacterialUnited States
-
West Penn Allegheny Health SystemCompletedAsthma | Allergic RhinitisUnited States